{"id":"W3130664242","doi":"10.1158/1538-7445.sabcs20-ot-32-02","title":"Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Medicine; Triple-negative breast cancer; Breast cancer; Chemotherapy; Internal medicine; Taxane; Metastatic breast cancer; Oncology; Cancer; Tumor microenvironment; Clinical trial; Phases of clinical research; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001467406,0.001263882,0.001314526,0.0002779024,0.0002782832,0.0009716279,0.0008147993,0.001520092,0.006288445],"category_scores_gemma":[0.0006302486,0.0004980863,0.0009687343,0.0002588303,0.000636806,0.0007934236,0.0002822972,0.003542657,0.001186247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008257991,"about_ca_system_score_gemma":0.001169376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008928048,"about_ca_topic_score_gemma":0.0024128,"domain_scores_codex":[0.9997312,0.0001214479,0.000009851966,0.00003997504,0.00003224094,0.00006511879],"domain_scores_gemma":[0.9995645,0.00005495158,0.00006898121,0.00003920469,0.0000297433,0.0002425674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6868973,0.09723022,0.005050518,0.001495101,0.001245639,0.0005077882,0.0003056136,0.002452197,0.07175769,0.0008009822,0.01416948,0.1180874],"study_design_scores_gemma":[0.597571,0.3793175,0.007740229,0.00008723999,0.0004033775,0.0005375225,0.00006022439,0.001234871,0.0054351,0.0002879951,0.007287593,0.00003726124],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839262,0.002905627,0.0006022543,0.0009064221,0.0002036068,0.004054403,0.002204425,0.0001784888,0.00501858],"genre_scores_gemma":[0.9687905,0.002661929,0.002525514,0.00182417,0.0002554115,0.005398156,0.004868247,0.00006264592,0.01361334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006288445,"threshold_uncertainty_score":0.02103692,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06885363079924274,"score_gpt":0.4511108196795613,"score_spread":0.3822571888803186,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}